Response to: Correspondence on "Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15" by Ataca Atilla and Atilla.
作者信息
Tian Gengwen, Courtney Amy N, Heczey Andras, Metelitsa Leonid S
机构信息
Baylor College of Medicine, Houston, Texas, USA.
Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
出版信息
J Immunother Cancer. 2025 Mar 5;13(3):e011858. doi: 10.1136/jitc-2025-011858.
Abstract
摘要
相似文献
1
Response to: Correspondence on "Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15" by Ataca Atilla and Atilla.对阿塔卡·阿提拉和阿提拉所著《应用表达GD2特异性嵌合抗原受体和IL-15的自然杀伤T细胞治疗后神经母细胞瘤患者的白细胞增多症》的通信回复
J Immunother Cancer. 2025 Mar 5;13(3):e011858. doi: 10.1136/jitc-2025-011858.
2
Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15.一名神经母细胞瘤患者在接受表达GD2特异性嵌合抗原受体和IL-15的自然杀伤T细胞治疗后出现高白细胞血症。
J Immunother Cancer. 2025 Jan 11;13(1):e010156. doi: 10.1136/jitc-2024-010156.
3
NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced Persistence and Antitumor Activity against Neuroblastoma.同时表达 GD2 特异性嵌合抗原受体和 IL15 的 NKT 细胞对神经母细胞瘤表现出增强的持久性和抗肿瘤活性。
Clin Cancer Res. 2019 Dec 1;25(23):7126-7138. doi: 10.1158/1078-0432.CCR-19-0421. Epub 2019 Sep 4.
4
Antibody-Dependent Cellular Cytotoxicity of iPS Cell-Derived Natural Killer T Cells by Anti-GD2 mAb for Neuroblastoma.抗GD2单克隆抗体介导的诱导多能干细胞衍生的自然杀伤T细胞对神经母细胞瘤的抗体依赖性细胞毒性作用
Cancer Sci. 2025 Apr;116(4):884-896. doi: 10.1111/cas.70008. Epub 2025 Feb 6.
5
Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.嵌合抗原受体修饰的不变自然杀伤 T 细胞为安全有效的肿瘤免疫治疗提供了新平台。
Blood. 2014 Oct 30;124(18):2824-33. doi: 10.1182/blood-2013-11-541235. Epub 2014 Jul 21.
6
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results.抗 GD2 CAR-NKT 细胞治疗复发或难治性神经母细胞瘤的 1 期临床试验中期结果更新
Nat Med. 2023 Jun;29(6):1379-1388. doi: 10.1038/s41591-023-02363-y. Epub 2023 May 15.
7
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis.抗 GD2 CAR-NKT 细胞治疗复发或难治性神经母细胞瘤的初步临床研究
Nat Med. 2020 Nov;26(11):1686-1690. doi: 10.1038/s41591-020-1074-2. Epub 2020 Oct 12.
8
Enhanced anti-tumor activity mediated by combination chimeric antigen receptor T cells targeting GD2 and GPC2 in high-risk neuroblastoma.嵌合抗原受体 T 细胞靶向 GD2 和 GPC2 增强高危神经母细胞瘤的抗肿瘤活性。
Cytotherapy. 2024 Nov;26(11):1308-1319. doi: 10.1016/j.jcyt.2024.05.023. Epub 2024 May 31.
9
Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.双唾液酸神经节苷脂特异性人类自然杀伤细胞对耐药性神经母细胞瘤有效。
Cancer Immunol Immunother. 2015 May;64(5):621-34. doi: 10.1007/s00262-015-1669-5. Epub 2015 Feb 25.
10
PRDM1 Is a Key Regulator of the NKT-cell Central Memory Program and Effector Function.PRDM1是NKT细胞中央记忆程序和效应功能的关键调节因子。
Cancer Immunol Res. 2025 Apr 2;13(4):577-590. doi: 10.1158/2326-6066.CIR-24-0259.
本文引用的文献
1
Modulating TNFα Activity to Address Cytokine Related Toxicity.调节肿瘤坏死因子α活性以应对细胞因子相关毒性。
J Immunother Cancer. 2025 Feb 27;13(2):e011724. doi: 10.1136/jitc-2025-011724.
2
Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15.一名神经母细胞瘤患者在接受表达GD2特异性嵌合抗原受体和IL-15的自然杀伤T细胞治疗后出现高白细胞血症。
J Immunother Cancer. 2025 Jan 11;13(1):e010156. doi: 10.1136/jitc-2024-010156.
3
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers.用于实体癌患者的白细胞介素-15武装的GPC3嵌合抗原受体T细胞。
Nature. 2025 Jan;637(8047):940-946. doi: 10.1038/s41586-024-08261-8. Epub 2024 Nov 27.
4
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.免疫治疗相关毒性管理，版本 1.2022，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2022 Apr;20(4):387-405. doi: 10.6004/jnccn.2022.0020.
5
Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia.调节 TNFα 活性可使表达 IL15 的 CLL-1 CAR T 细胞安全地消除急性髓细胞白血病。
J Immunother Cancer. 2020 Sep;8(2). doi: 10.1136/jitc-2020-001229.
6
NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced Persistence and Antitumor Activity against Neuroblastoma.同时表达 GD2 特异性嵌合抗原受体和 IL15 的 NKT 细胞对神经母细胞瘤表现出增强的持久性和抗肿瘤活性。
Clin Cancer Res. 2019 Dec 1;25(23):7126-7138. doi: 10.1158/1078-0432.CCR-19-0421. Epub 2019 Sep 4.
7
Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15.经优化的 GD2 特异性嵌合抗原受体和白细胞介素-15 转导 T 细胞根除神经母细胞瘤。
Clin Cancer Res. 2019 May 1;25(9):2915-2924. doi: 10.1158/1078-0432.CCR-18-1811. Epub 2019 Jan 7.
8
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.ASTCT 细胞因子释放综合征和免疫效应细胞相关神经系统毒性的共识分级标准。
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25.
Zotero 插件